| Dosage Form: | Powder Injection |
|---|---|
| Transport Package: | Carton |
| Specification: | 1g |
| Trademark: | Sinolead |
| Origin: | China |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Generic Name | Gemcitabine Hydrochloride for Injection 1g |
| Strength | 1g |
| Packing | 1vial/box |
| Origin | China |
This product can be used to treat the following diseases:
- Locally advanced or metastatic non-small cell lung cancer;
-- Locally advanced or metastatic pancreatic cancer;
Gemcitabine in combination with paclitaxel is indicated for the treatment of unresectable, locally recurrent or metastatic breast cancer that has recurred after adjuvant/neoadjuvant chemotherapy. Anthracyclines should have been used in previous chemotherapy unless clinically contraindicated.
This product should be used under the guidance of an experienced oncologist. It is recommended to refer to existing clinical trial data and adjust the dosage according to individual clinical conditions.
dose
Adult:
Non-small cell lung cancer
Monotherapy:
The recommended dose of gemcitabine is 1000mg/m2 intravenously for 30 minutes. After 3 weeks of treatment, rest for 1 week and repeat the above 4-week treatment cycle. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered per treatment cycle or within one treatment cycle.
Combination therapy:
Gemcitabine combined with cisplatin has two treatment options: 3-week therapy and 4-week therapy.
3-week therapy: The recommended dose of gemcitabine is 1250mg/m2 for 30 minutes intravenously. Dosing was given on day 1, day 8, and day 15 of every 28-day treatment cycle. Depending on the patient's tolerance to gemcitabine, a dose reduction may be considered per treatment cycle or within one treatment cycle.
Liver insufficiency
Gemcitabine given to patients who have already developed liver metastases or who have a history of hepatitis, alcoholism, or cirrhosis may worsen underlying liver dysfunction.
Laboratory evaluations of kidney and liver function, including virological tests, should be performed regularly.
Because there is not enough information from clinical studies on clear dose recommendations for these patient populations, gemcitabine should be used with caution in patients with liver insufficiency or renal impairment, as clinical studies in these patients do not have sufficient data to make a clear dose recommendation.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}